Design and Synthesis of Peptidomimetic Protein Farnesyltransferase Inhibitors as Anti-Trypanosoma brucei Agents

Journal of Medicinal Chemistry

Volumn 47, Issue 2, 2004, Pages 432-445

  Ohkanda, Junko ^a   Buckner, Frederick S ^b   Lockman, Jeffrey W ^a   Yokoyama, Kohei ^b   Carrico, Dora ^a   Eastman, Richard ^b   De Luca Fradley, Kate ^c   Davies, Wendy ^c   Croft, Simon L ^c   Van Voorhis, Wesley C ^b   Gelb, Michael H ^b   Sebti, Saïd M ^d   Hamilton, Andrew D ^a  

^a YALE UNIVERSITY   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^d H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITRYPANOSOMAL AGENT; FTI 2148; GGTI 297; IMIDAZOLE DERIVATIVE; N [[5 [(2 AMINO 3 MERCAPTOPROPYL)AMINO][1,1' BIPHENYL] 2 YL]CARBONYL]METHIONINE; N [[5 [(2 AMINO 3 MERCAPTOPROPYL)AMINO][1,1' BIPHENYL] 2 YL]CARBONYL]METHIONINE METHYL ESTER; PROTEIN FARNESYLTRANSFERASE INHIBITOR; UNCLASSIFIED DRUG;

AFRICAN TRYPANOSOMIASIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG CYTOTOXICITY; DRUG DESIGN; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME INHIBITION; ENZYME SUBSTRATE; EVALUATION; HYDROPHOBICITY; INHIBITION KINETICS; ISOMERISM; MAMMAL; MOUSE; NONHUMAN; TRYPANOSOMA BRUCEI; TRYPANOSOMA RHODESIENSE;

ALKYL AND ARYL TRANSFERASES; ANIMALS; DRUG DESIGN; FARNESYLTRANSTRANSFERASE; IMIDAZOLES; METHIONINE; MOLECULAR MIMICRY; PEPTIDES; STRUCTURE-ACTIVITY RELATIONSHIP; TRYPANOCIDAL AGENTS; TRYPANOSOMA BRUCEI BRUCEI; TRYPANOSOMA BRUCEI RHODESIENSE;

EID: 9144248974     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm030236o     Document Type: Article

References (27)

1. www.who.int/tdr/.
2. Sebti, S. M.; Hamilton, A. D. Farnesyltransferase inhibitors in cancer therapy; Humana Press: New Jersey, 2000.
3. Sebti, S. M.; Hamilton, A. D. Farnesyltransferase and geranylgeranyltransferase I inhibitors in cancer therapy: Important mechanistic and bench to bedside issues. Exp. Opin. Invest. Drugs 2000, 9, 2767-2782.
4. Qian, Y.; Vogt, A.; Sebti, S. M.; Hamilton, A. D. Design and synthesis of non-peptide Ras CAAX mimetics as potent farnesyltransferase inhibitors. J. Med. Chem. 1996, 39, 217-223.
5. Qian, Y.; Marugan, J. J.; Fossum, R. D.; Vogt, A.; Sebti, S. M.; Hamilton, A. D. Probing the hydrophobic pocket of farnesyltransferase: Aromatic substitution of CAAX peptidomimetics leads to highly potent inhibitors. Bioorg. Med. Chem. 1999, 7, 3011-3024.
6. Ohkanda, J.; Lockman, J. W.; Kothare, M. A.; Qian, Y.; Blaskovich, M. A. ; Sebti, S. M.; Hamilton, A. D. Design and synthesis of potent nonpeptidic farnesyltransferase inhibitors based on a terphenyl scaffold. J. Med. Chem. 2002, 45, 177-188.
7. Sun, J. B.; Blaskovich, M. A.; Knowles, D.; Qian, Y.; Ohkanda, J.; Bailey, R. D.; Hamilton, A. D.; Sebti, S. M. Antitumor efficacy of a novel class of nonthiol-containing peptidomimetic inhibitors of farnesyltransferase and geranylgeranyltransferase I: Combination therapy with the cytotoxic agents Cisplatin, Taxol, and Gemcitabine. Cancer Res. 1999, 59, 4919-4926.
8. Yokoyama, K.; Lin, Y.; Stuart, K. D.; Gelb, M. H. Prenylation of proteins in Trypanosoma brucei. Mol. Biochem. Parasitol. 1997, 87, 61-69.
9. Field, H.; Blench, I.; Croft, S.; Field, M. C. Characterization of protein isoprenylation in procyclic form Trypanosoma brucei. Mol. Biochem. Parasitol. 1996, 82, 67-80.
10. Yokoyama, K.; Trobridge, P.; Buckner, F. S.; Scholten, J.; Stuart, K. D. ; Voorhis, W. C. V.; Gelb, M. H. The effects of protein farnesyltransferase inhibitors on trypanosomatids: Inhibition of protein farnesylation and cell growth. Mol. Biochem. Parasitol. 1998, 94, 87-97.
11. Chakrabarti, D.; Azam, T.; DelVecchio, C.; Qiu, L.; Park, Y.; Allen, C. M. Protein prenyltransferase activities of Plasmodium falciparum. Mol. Biochem. Parasitol. 1998, 94, 175-184.
12. Yokoyama, K.; Trobridge, P.; Buckner, F. S.; Voorhis, W. C. V.; Stuart, K. D.; Gelb, M. H. Protein farnesyltransferase from Trypanosoma brucei. A heterodimer of 61- and 65-kDa subunits as a new target for antiparasite therapeutics. J. Biol. Chem. 1998, 273, 26497-26505.
13. Ohkanda, J.; Lockman, J. W.; Yokoyama, K.; Gelb, M. H.; Croft, S. L.; Kendrick, H.; Harrell, M. I.; Feagin, J. E.; Blaskovich, M. A.; Sebti, S. M.; Hamilton, A. D. Peptidomimetic inhibitors of protein farnesyltransferase show potent antimalarial activity. Bioorg. Med. Chem. Lett. 2001, 11, 761-764.
14. Chakrabarti, D.; Silva, T. D.; Barger, J.; Paquette, S.; Patel, H.; Patterson, S.; Allen, C. M. Protein farnesyltransferase and protein prenylation in Plasmodium falciparum. J. Biol. Chem. 2002, 277, 42066-42073.
15. Sebti, S. M.; Hamilton, A. D. Inhibition of Ras prenylation: A novel approach to cancer chemotherapy. Pharmacol. Ther. 1997, 74, 103-114.
16. Leonard, D. M. Ras farnesyltransferase: A new therapeutic target. J. Med. Chem. 1997, 40, 2971-2989.
17. Long, S. B.; Casey, P. J.; Beese, L. S. The basis for K-Ras4B binding specificity to protein farnesyltransferase revealed by 2 Å resolution ternary complex structures. Structure 2000, 8, 209-222.
18. Strickland, C. L.; Windsor, W. T.; Syto, R.; Wang, L.; Bond, R.; Wu, Z.; Schwartz, J.; Le, H. V.; Weber, P. C. Crystal structure of farnesyl protein transferase complexed with a CaaX peptide and farnesyl diphosphate analogue. Biochemistry 1998, 37, 16601-16611.
19. Sun, J.; Qian, Y.; Hamilton, A. D.; Sebti, S. M. Ras CAAX peptidomimetic FTI 276 selectively blocks tumor growth in nude mice of a human lung carcinoma with K-Ras mutation and p53 deletion. Cancer Res. 1995, 55, 4243-4247.
20. Buckner, F. S.; Yokoyama, K.; Nguyen, L.; Grewal, A.; Erdjument-Bromage, H.; Tempst, P.; Strickland, C. L.; Xiao, L.; Voorhis, W. C. V.; Gelb, M. H. Cloning, heterologous expression, and distinct substrate specificity of protein farnesyltransferase from Trypanosoma brucei. J. Biol. Chem. 2000, 275, 21870-21876.
21. Ohkanda, J.; Strickland, C. L.; Carrico, D.; Lockman, J. W.; Blaskovich, M. A.; Sun, J.; Sebti, S. M.; Hamilton, A. D. In preparation.
22. Karp, J. E.; Kaufmann, S. H.; Adjei, A. A.; Lancet, J. E.; Wright, J. J. ; End, D. W. Current status of clinical trials of farnesyltransferase inhibitors. Curr. Opin. Oncol. 2001, 13, 470-476.
23. Matsui, T.; Sugiura, T.; Nakai, H.; Iguchi, S.; Shigeoka, S.; Takada, H. ; Odagaki, Y.; Nagao, Y.; Ushio, Y.; Ohmoto, K.; Iwamura, H.; Yamazaki, S.; Arai, Y.; Kawamura, M. Novel 5-HT3 antagonists-Isoquinolinones and 3-aryl-2-pyridones. J. Med. Chem. 1992, 35, 3307-3319.
24. Buckner, F. S.; Eastman, R. T.; Nepomuceno-Silva, J. L.; Speelmon, E. C. ; Myler, P. J.; Voorhis, W. C. V.; Yokoyama, K. Cloning, heterologous expression, and substrate specificities of protein farnesyltransferases from Trypanosoma cruzi and Leishmania major. Mol. Biochem. Parasitol. 2002, 122, 181-188.
25. Pompliano, D. L.; Schaber, M. D.; Mosser, S. D.; Shafer, J. A.; Gibbs, J. B. Isoprenoid diphosphate utilization by recombinant human farnesyl: protein transferase: Interactive binding between substrates and a preferred kinetic pathway. Biochemistry 1993, 32, 8341-8347.
26. Hirumi, H.; Hirumi, K. Continuous cultivation of Trypanosoma brucei blood stream forms in a medium containing a low concentration of serum protein without feeder cell layers. J. Parasitol. 1989, 75, 5469-5472.
27. Raz, B.; Iten, M.; Grether-Buhler, Y.; Kaminsky, R.; Brun, R. The Alamar Blue assay to determine drug sensitivity of African trypanosomes (T.b. rhodesiense and T.b. gambiense) in vitro. Acta Trop. 1997, 68, 139-147.